Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluid administration Clear all

Conditions: Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Interventions: UX007, Placebo; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year to 100 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Orlando, Florida + 4 more

Conditions: Lower Limb Amputation Below Knee (Injury)
Interventions: Adjustable socket; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Traumatic Brain Injury (TBI) Patients
Interventions: Normal Saline (0.9% NaCl), balanced crystalloid; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: Adhansia XR, Concerta; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 12 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 35
States / cities: Dothan, Alabama • Beverly Hills, California • Cromwell, Connecticut + 31 more

Conditions: Colonic Disease
Interventions: Feasibility Assessment; Device
Lead sponsor: WAE Medical; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Wounds and Injuries, Multiple Trauma, Disorder of Fluid Balance
Interventions: Plasmalyte A, Normal Saline; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Overactive Bladder, Parkinson Disease
Interventions: solifenacin, Pelvic floor muscle exercise-based behavioral therapy; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Birmingham, Alabama • Decatur, Georgia • Philadelphia, Pennsylvania + 1 more

Conditions: Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry; Dietary Supplement · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Renal Transplant Rejection
Interventions: Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy; Drug · Other · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Electronic Nicotine Delivery System Flavors
Interventions: Tobacco product administration and assessment; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Heart Failure, Kidney Disease
Interventions: Not listed
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: North Brunswick, New Jersey

Conditions: Tobacco-Related Carcinoma
Interventions: Biospecimen Collection, Carbon Monoxide Measurement, Vaping session, Survey Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 65 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Interventions: Not listed
Lead sponsor: Adela, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Duarte, California • Miami, Florida • Gainesville, Georgia + 14 more

Conditions: Sarcoma
Interventions: Non-Metastatic and Resectable, Metastatic and Un-resectable, No evidence of disease, under surveillance, ALT or WDLS; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Entolimod, Placebo, Influenza vaccine; Drug
Lead sponsor: Robert J. Pignolo; Other
Eligibility: 65 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Pyruvate Dehydrogenase Complex Deficiency
Interventions: Dichloroacetate (DCA), Placebo, Genotype; Drug · Other · Genetic
Lead sponsor: Saol Therapeutics Inc; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 10
States / cities: Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more

Conditions: Glioblastoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: pralatrexate, fluorouracil, laboratory biomarker analysis, DNA analysis, high performance liquid chromatography, polymerase chain reaction, nucleic acid sequencing, pharmacological study, pharmacogenomic studies, polymorphism analysis; Drug · Other · Genetic
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Ebola Virus Infection
Interventions: B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Rilpivirine, Placebo; Drug
Lead sponsor: PATH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Newark, New Jersey • The Bronx, New York

Conditions: Solid Tumor
Interventions: Sirolimus, Cyclophosphamide, Etoposide, Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Colorectal Cancer
Interventions: Accelerated Recovery Plan, Early Discharge, Telemedicine, Standard Enhanced Care; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Cancer
Interventions: Canakinumab, Tislelizumab, Nab-Paclitaxel, Gemcitabine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: New York, New York

Conditions: Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
Interventions: Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Auto Control of Volume Management for Limb Loss

Saline Versus Balanced Crystalloid in Traumatic Brain Injury

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Performance of the Poseidon System for Fluid Management During Water-aided Colonoscopy

Normal Saline Versus Plasmalyte in Initial Resuscitation of Trauma Patients

Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers

Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis

Manipulating E-Cigarette Nicotine to Promote Public Health

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy and Spectroscopy-based Molecular Urinalysis in Sarcoma Patients

Entolimod on Immunosenescence in Healthy Geriatric Subjects Receiving Influenza Vaccination

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Shaping Anesthetic Techniques to Reduce Post-operative Delirium